SEC Comment Letter 0000000000-24-000762 to Opus Genetics, Inc. (IRD)
Opus Genetics, Inc.
Date: Jan. 19, 2024 · CIK: 0001228627 · Accession: 0000000000-24-000762
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276462
Letter
United States securities and exchange commission logo January 19, 2024 George Magrath Chief Executive Officer Ocuphire Pharma, Inc. 7000 Grand River Avenue, Suite 120 Farmington Hills, MI 48335 Re:Ocuphire Pharma, Inc. Registration Statement on Form S-3 Filed January 10, 2024 File No. 333-276462 Dear George Magrath: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Emily Johns
Show Raw Text
United States securities and exchange commission logo
January 19, 2024
George Magrath
Chief Executive Officer
Ocuphire Pharma, Inc.
7000 Grand River Avenue, Suite 120
Farmington Hills, MI 48335
Re:Ocuphire Pharma, Inc.
Registration Statement on Form S-3
Filed January 10, 2024
File No. 333-276462
Dear George Magrath:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Emily Johns